Shire (LSE:SHP)
Drugs group Shire was founded in 1986, and became a listed company in 1996. It specialises in the treatment of rare diseases.
About
Last updated 15-11-2019, 01:10:31pm GMTRelated Articles
-
Why I’d snap up the GSK share price for Christmas
I think the GlaxoSmithKline plc (LON: GSK) share price is lagging behind the turnaround in the company's fortunes. Read More »
-
Worried about the next recession? Consider these FTSE 100 defensives
Non-cyclical sales growth and rising profits should make these FTSE 100 (INDEXFTSE: UKX) stocks a must-consider for nervous investors. Read More »
-
Could these 2 pharma growth stocks help you retire early?
Harvey Jones sees plenty to like in these two pharmaceutical stocks, but plenty of uncertainties too. Read More »
-
One dirt-cheap FTSE 100 stock I’d buy today and one I’d sell
Royston Wild looks at two FTSE 100 (INDEXFTSE: UKX) shares with very different investment outlooks. Read More »
-
Why I’d pile into FTSE 100 takeover candidate Shire along with this promising life science play
FTSE 100 (INDEXFTSE: UKX) pharmaceutical firm Shire plc (LON: SHP) still looks attractive to me alongside this potential grower. Read More »
-
Two FTSE 100 growth stocks I’d buy with £2,000 today
These two FTSE 100 (INDEXFTSE: UKX) shares could offer growth at a reasonable price. Read More »
-
One ‘secret’ growth stock I’d buy alongside this FTSE 100 growth monster
This hidden growth stock is gearing up to become the next FTSE 100 (INDEXFTSE:UKX) growth champion. Read More »
-
Looking to invest £2,000? Here are 2 pharma stocks I’d buy today
Harvey Jones says these two pharmaceutical stocks have something to please both momentum and contrarian investors. Read More »
-
2 top FTSE 100 defensive stocks for bargain hunting investors
Wide moats to entry, high growth potential and attractive valuations have these FTSE 100 (INDEXFTSE: UKX) stocks at the top of my watch list.... Read More »
-
2 pharma stocks I’d buy in March
G A Chester discusses two stocks he'd buy in the under-performing pharmaceuticals sector. Read More »